Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
31 studies found for:    poly iclc | Open Studies
Show Display Options
Rank Status Study
1 Recruiting In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®
Conditions: Melanoma;   Head and Neck Cancer;   Sarcoma;   Non-Melanoma Skin Cancers
Intervention: Biological: Hiltonol
2 Recruiting A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas
Condition: Brain Tumors
Intervention: Drug: Poly ICLC
3 Not yet recruiting Pembrolizumab + Poly-ICLC in MRP Colon Cancer
Conditions: Metastatic Colon Cancer;   Solid Tumor
Interventions: Drug: pembrolizumab;   Drug: Poly-ICLC
4 Recruiting In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy
Condition: Low-Grade B-cell Lymphoma
Interventions: Drug: rhuFlt3L/CDX-301;   Drug: Poly-ICLC
5 Not yet recruiting The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer
Conditions: Cancer of Ovary;   Neoplasms, Ovarian;   Ovarian Cancer Stage IV;   Ovarian Cancer Recurrent;   Ovarian Cancer Stage III;   Ovary Cancer
Interventions: Biological: Oregovomab;   Drug: Poly ICLC
6 Recruiting A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)
Conditions: Glioma;   Malignant Glioma;   Astrocytoma, Grade II;   Oligodendroglioma;   Glioma, Astrocytic;   Oligoastrocytoma, Mixed
Interventions: Biological: IMA950;   Biological: poly-ICLC;   Biological: Varlilumab
7 Recruiting A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers
Conditions: Head and Neck Squamous Cell Carcinoma;   Breast Cancer;   Sarcoma;   Merkel Cell Carcinoma;   Cutaneous T-Cell Lymphoma;   Melanoma;   Renal Cancer;   Bladder Cancer;   Prostate Cancer
Interventions: Drug: Durvalumab;   Drug: Tremelimumab;   Drug: Poly ICLC
8 Recruiting DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
Conditions: Fallopian Tube Carcinoma;   Ovarian Carcinoma;   Primary Peritoneal Carcinoma
Interventions: Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401;   Drug: Epacadostat;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Poly ICLC
9 Recruiting A Vaccine Trial for Low Grade Gliomas
Condition: Low Grade Glioma
Intervention: Biological: Experimental: HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC
10 Recruiting A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas
Conditions: Newly Diagnosed Pediatric Pontine Glioma;   Newly Diagnosed Pediatric High Grade Glioma;   Recurrent Pediatric High Grade Glioma;   Recurrent Pediatric Low Grade Glioma
Interventions: Biological: HLA-A2 restricted glioma antigen peptides vaccine;   Biological: Poly-ICLC
11 Not yet recruiting Neoepitope-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors
Condition: Pediatric Brain Tumor
Interventions: Biological: Personalized peptide vaccine;   Drug: Poly ICLC;   Procedure: Peripheral blood draw
12 Recruiting Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies
Condition: Solid Tumors
Interventions: Biological: Peptides;   Drug: Poly-ICLC;   Drug: Lenalidomide
13 Recruiting Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma
Conditions: Oligodendroglioma;   Astrocytoma, Grade II;   Glioma, Astrocytic;   Glioma;   Malignant Glioma;   Oligoastrocytoma, Mixed
Interventions: Biological: GBM6-AD and poly-ICLC before and after surgery;   Biological: GBM6-AD and poly-ICLC after surgery only
14 Recruiting Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma
Condition: Cutaneous T-cell Lymphoma
Interventions: Drug: Romidepsin;   Drug: Poly ICLC;   Radiation: Focal lesional radiation
15 Recruiting Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma
Conditions: Glioblastoma Multiforme;   Astrocytoma, Grade IV
Interventions: Biological: Personalized peptide vaccine;   Drug: Poly-ICLC;   Drug: Temozolomide
16 Recruiting A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence
Condition: Melanoma
Interventions: Biological: DC Vaccine;   Biological: Montanide Vaccine;   Biological: Poly-ICLC
17 Recruiting Autologous OC-L Vaccine and Ovarian Cancer
Conditions: Primary Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
Interventions: Biological: OC-L;   Other: Montanide;   Other: poly-ICLC (Hiltonol),
18 Not yet recruiting A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma
Conditions: Glioblastoma;   Glioma
Interventions: Drug: Bevacizumab;   Biological: Peptide Vaccine;   Drug: Poly-ICLC as immune adjuvant;   Drug: Keyhole limpet hemocyanin (KLH)
19 Recruiting A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma
Condition: Melanoma
Interventions: Biological: Poly-ICLC;   Biological: Peptides
20 Recruiting Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Conditions: Triple Negative Breast Cancer;   Triple Negative Breast Neoplasms;   Triple-Negative Breast Cancer
Interventions: Biological: Personalized synthetic long peptide vaccine (Poly ICLC);   Drug: Poly ICLC

   Previous Page Studies Shown (1-20) Next Page (21-31) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.